BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25330770)

  • 1. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
    Liu JC; Voisin V; Wang S; Wang DY; Jones RA; Datti A; Uehling D; Al-awar R; Egan SE; Bader GD; Tsao M; Mak TW; Zacksenhaus E
    EMBO Mol Med; 2014 Dec; 6(12):1542-60. PubMed ID: 25330770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN.
    Russnes HG; Caldas C
    EMBO Mol Med; 2014 Dec; 6(12):1512-4. PubMed ID: 25471453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
    Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
    Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
    Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
    Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
    Ju Y; Ben-David Y; Rotin D; Zacksenhaus E
    Sci Rep; 2021 Apr; 11(1):9181. PubMed ID: 33911160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.
    Gasparyan M; Lo MC; Jiang H; Lin CC; Sun D
    J Biol Chem; 2020 Aug; 295(34):12188-12202. PubMed ID: 32467227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
    Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
    Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
    BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 13. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
    Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
    Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
    Pires MM; Hopkins BD; Saal LH; Parsons RE
    Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the tumor suppressor PTEN in triple-negative breast cancer.
    Chai C; Wu HH; Abuetabh Y; Sergi C; Leng R
    Cancer Lett; 2022 Feb; 527():41-48. PubMed ID: 34902523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
    Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
    J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
    Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
    Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
    Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
    J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
    Karakas D; Ozpolat B
    J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.